SCHEMBL4382780

SCHEMBL4382780

C#CC(C)(C)N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HPGD P15428 1/20 0.46
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
RECQL P46063 1/20 0.44
HRH3 Q9Y5N1 1/20 0.43
EPHX2 P34913 1/20 0.42
EPHX1 P07099 1/20 0.41
STS P08842 1/20 0.41
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
LMNA P02545 1/20 0.40
PTPN2 P17706 1/20 0.40
PTPN1 P18031 1/20 0.40
PTPN6 P29350 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL190131 0.83 USP2 (0.50) USP2SMN1; SMN2HPGDKMT2AMEN1
SCHEMBL14356627 0.81 USP2 (0.49) USP2SMN1; SMN2HPGDKMT2AMEN1
SCHEMBL5710798 0.81 ALDH1A1 (0.53) SMN1; SMN2KMT2AMEN1RECQLHRH3
SCHEMBL698803 0.81 USP2 (0.69) USP2SMN1; SMN2HPGDKMT2AMEN1
SCHEMBL18294 0.81 USP2 (0.69) USP2SMN1; SMN2HPGDKMT2AMEN1
SCHEMBL1778561 0.80 USP2 (0.58) USP2SMN1; SMN2HPGDKMT2AMEN1
SCHEMBL25362960 0.79 USP2 (0.53) USP2SMN1; SMN2HPGDKMT2AMEN1
SCHEMBL27036913 0.79 USP2 (0.53) USP2SMN1; SMN2HPGDKMT2AMEN1
SCHEMBL6600585 0.78 HRH3 (0.47) KMT2AMEN1HRH3LMNA
SCHEMBL2175867 0.78 HRH3 (0.47) KMT2AMEN1HRH3ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421207-B2 Pyrimidinedione-based compounds as AXL, c-MET, and Mer inhibitors and methods of use thereof CMG PHARMACEUTICAL CO., LTD. (KR) 2025-09-23 US disclosed
US-20250171426-A1 PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF CMG PHARMACEUTICAL CO., LTD. (KR) 2025-05-29 US disclosed
EP-4479397-A1 PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF CMG Pharmaceutical Co., Ltd. (KR) 2024-12-25 EP disclosed
CN-118510770-A Fused heteroaryl hydroxamic acids as STING agonists 比西切姆有限公司 2024-08-16 CN disclosed
US-20230348423-A1 PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF CMG PHARMACEUTICAL CO., LTD. (KR) 2023-11-02 US disclosed
US-20230348423-A1 PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF CMG PHARMACEUTICAL CO., LTD. (KR) 2023-11-02 US disclosed
US-20230348423-A1 PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF CMG PHARMACEUTICAL CO., LTD. (KR) 2023-11-02 US disclosed
WO-2023156864-A1 PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF CMG PHARMACEUTICAL CO., LTD. (KR) 2023-08-24 WO disclosed
WO-2023156864-A1 PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF CMG PHARMACEUTICAL CO., LTD. (KR) 2023-08-24 WO disclosed
WO-2023156863-A1 PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF CMG PHARMACEUTICAL CO., LTD. (KR) 2023-08-24 WO disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
US-20040019039-A1 Substituted piperazines and diazepanes HIGH POINT PHARMACEUTICALS, LLC 2004-01-29 US disclosed
US-5686610-A Pyridyl piperazine compound PHARMACIA & UPJOHN COMPANY (US) 1997-11-11 US disclosed
US-5599930-A Substituted indoles as anti-AIDS pharmaceuticals THE UPJOHN COMPANY (US) 1997-02-04 US disclosed
WO-1993001181-A1 SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICALS THE UPJOHN COMPANY (US) 1993-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 USP2 2350/4885SMN1; SMN2 2684/4885HPGD 646/4885
US-20250171426-A1 PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF MERTK, AXL, RET USP2 4345/4885SMN1; SMN2 3670/4885HPGD 3665/4885
US-20040019039-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 USP2 2350/4885SMN1; SMN2 2684/4885HPGD 646/4885
US-12421207-B2 Pyrimidinedione-based compounds as AXL, c-MET, and Mer inhibitors and methods of use thereof MERTK, AXL, MET USP2 4335/4885SMN1; SMN2 3855/4885HPGD 3779/4885
US-20230348423-A1 PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF MERTK, AXL, MET USP2 4335/4885SMN1; SMN2 3855/4885HPGD 3779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.